Table 2 Characteristics of patients who underwent PCI and CYP2C19 genotyping over the first 12 months
Characteristic | n = 392 |
|---|---|
Age (years) | 63 ± 11 |
Male sex | 271 (69) |
Race | |
 White | 292 (74.5) |
 Black | 93 (23.7) |
 Asian | 3 (0.8) |
 Other or not reported | 4 (1.0) |
Past medical history | |
 Stroke or TIA | 48 (12.2) |
 Gastrointestinal hemorrhage | 7 (1.8) |
 Intracranial hemorrhage | 2 (0.5) |
PCI indication | |
 STEMI | 74 (18.9) |
 NSTEMI | 99 (25.2) |
 Unstable angina | 174 (44.4) |
 Stable coronary disease | 45 (11.5) |
P2Y12 inhibitor on admission | |
 Clopidogrel | 99 (25.3) |
 Prasugrel | 9 (2.3) |
 Ticagrelor | 13 (3.3) |
 Other or not available | 11 (2.8) |
Anticoagulant on admissiona | |
 Warfarin | 9 (2.3) |
 Direct oral anticoagulant | 12 (3.0) |
 Low molecular weight heparin | 1 (0.3) |
 Not available | 9 (2.3) |
Anticoagulant at dischargea | |
 Warfarin | 16 (4.1) |
 Direct oral anticoagulant | 16 (4.1) |
 Low molecular weight heparin | 1 (0.3) |
CYP2C19 phenotype | |
 Poor metabolizer (*2/*2) | 7 (1.8) |
 Intermediate metabolizer (*1/*2, *2/*17) | 106 (27.0) |
 Normal metabolizer (*1/*1) | 145 (37.0) |
 Rapid metabolizer (*1/*17) | 110 (28.1) |
 Ultra-rapid metabolizer (*17/*17) | 20 (5.1) |
 Inconclusive | 4 (1.0) |